Skip to main content

Table 2 Novel cytotoxic agents under investigation or approved for metastatic breast cancer

From: Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer

Agent

Drug class

Stage of development in breast cancer

Nanoparticle albumin-bound (nab-) paclitaxel

Taxane

Approved

Larotaxel

Taxane

III

Ixabepilone

Epothilone

Approved

Patupilone

Epothilone

II

ZK-EPO

Epothilone

II

BMS-310705

Epothilone

I

KOS-862

Epothilone

Discontinued

Vinflunine

Vinca alkaloid

II

Eribulin

Mitotic inhibitor

III

Trabectedin

Nucleotide excision repair inhibitor, cell cycle inhibitor

III